AI Article Synopsis
- This study assessed the effectiveness of changes in the apparent diffusion coefficient (ADC) at MRI one month post-transcatheter arterial chemoembolization (TACE) for liver cancer (HCC), comparing it to standard response criteria like RECIST and mRECIST.
- Thirty-eight patients underwent MRI before and after TACE, with results showing that the ADC ratio was a strong predictor of progression-free survival (PFS), outperforming traditional criteria.
- The findings suggest that the ADC ratio not only correlates well with tumor response but is also significantly linked to histopathologic necrosis, emphasizing its potential as a reliable predictor for patient prognosis.
Article Abstract
Purpose: To evaluate the predictive utility of apparent diffusion coefficient (ADC) changes at diffusion-weighted (DW) magnetic resonance (MR) imaging 1 month after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) compared with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, European Association for the Study of the Liver (EASL) criteria, and modified RECIST (mRECIST).
Materials And Methods: Institutional review board approval and informed consent were obtained for this prospective study. Thirty-eight patients with inoperable HCC underwent 1.5-T MR imaging, including DW imaging, before and 1 month after TACE. Responses 1 month after TACE were assessed with the ADC change relative to baseline (ADC ratio), RECIST, EASL criteria, and mRECIST. Eight patients underwent transplantation 4 months after TACE, allowing the association between response and histopathologic necrosis ratio to be determined. In 30 patients, Kaplan-Meier and log-rank tests were used to correlate the response variables with progression-free and overall survival.
Results: Median progression-free survival (PFS) was 5 months, and overall survival was 17.5 months. Survival analyses showed significant effects of pretreatment α-fetoprotein level (P = .03) and ADC ratio (P < .0001) on PFS and substantial effects of mRECIST, RECIST, and EASL criteria (.05 < P < .1). ADC ratio was a significant predictor of 5-month PFS (P < .001), with an accuracy of 93.3% compared with 53.3% with mRECIST and EASL criteria and 66.7% with RECIST. No response variables correlated with overall survival. Only the ADC ratio was significantly associated with histopathologic tumor necrosis (P = .03).
Conclusion: The ADC ratio 1 month after TACE was an independent predictor of PFS, which showed stronger association with tumor response than did RECIST, EASL criteria, or mRECIST.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1148/radiol.13130591 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.
J Hepatol
December 2024
Liver cancer is the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) accounting for approximately 90% of primary liver cancers. Advances in diagnostic and therapeutic tools, along with improved understanding of their application, are transforming patient treatment. Integrating these innovations into clinical practice presents challenges and necessitates guidance.
View Article and Find Full Text PDFHepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances.
Cancers (Basel)
November 2024
Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Background/objectives: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis. Early detection through regular surveillance is crucial for improving patient outcomes, especially in high-risk groups such as those with cirrhosis or chronic hepatitis B. Geographic variations in HCC risk factors, including viral hepatitis and non-alcoholic fatty liver disease (NAFLD), have led to the development of different international surveillance guidelines.
View Article and Find Full Text PDFHepatocellular carcinoma risk scores for non-viral liver disease: A systematic review and meta-analysis.
JHEP Rep
January 2025
Leeds Institute for Medical Research, University of Leeds, Leeds, United Kingdom.
Background & Aims: Hepatocellular carcinoma (HCC) risk prediction models may provide a more personalised approach to surveillance for HCC among patients with cirrhosis. This systematic review aims to summarise the performance of HCC prediction models in patients with non-viral chronic liver disease.
Method: The study was prospectively registered with PROSPERO (ID: CRD42022370078) and reported in accordance with PRISMA guidelines.
The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines.
J Hepatol
December 2024
Department of metabolism Digestion and Reproduction, Division of Digestive Diseases, St Mary's Hospital, Liver Unit, Imperial College London, UK; Medical Research Council @ the London School of Hygiene and Tropical Medicine The Gambia Unit, Fajara, The Gambia. Electronic address:
Progress towards hepatitis B virus (HBV) global elimination has been slow and most countries are far to reach the elimination targets set up by the World Health Organization (WHO). The burden of chronic hepatitis B is mainly bear by resource-limited countries where only a minority of people living with HBV are diagnosed and treated and international guidelines hardly applicable in real-life. In March 2024, the WHO released its revised guidelines for the prevention and management of chronic hepatitis B.
View Article and Find Full Text PDFEarly HBcrAg and Anti-HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation-A Pooled Analysis of Two Clinical Trials.
Aliment Pharmacol Ther
December 2024
Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Background: Severe flares (ALT ≥ 10×ULN) are a well-recognised adverse outcome after nucleos(t)ide analogue (NA) cessation and may lead to liver failure. Thus, identification of patients at risk for these flares is of major importance.
Methods: Data were used from two prospective studies on NA cessation conducted in the Netherlands and Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!